Cochrane · systematic review · CD009831
Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders
Dold, M, Samara, MT, Li, C, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
11
current version
GRADE rated
11
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 6 · 54.5%Low 5 · 45.5%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Haloperidol versus first‐generation antipsychotics for schizophrenia (short term)
Population: people with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinically important response to treatment (short term) Haloperidol vs first‐generation antipsychotics | RR 0.93 [0.87, 1] | 40 studies · 2132 participants | Low Downgraded: risk of bias, inconsistency |
Leaving the study early due to any reason as a measure of overall acceptability (short term) Haloperidol vs first‐generation antipsychotics | RR 1.04 [0.87, 1.24] | 28 studies · 1299 participants | Low Downgraded: risk of bias, inconsistency |
Leaving the study early due to inefficacy of treatment as a measure of overall efficacy (short term) Haloperidol vs first‐generation antipsychotics | RR 0.93 [0.4, 2.16] | 13 studies · 507 participants | Very low Downgraded: risk of bias, inconsistency |
Leaving the study early due to adverse events as a measure of overall tolerability (short term) Haloperidol vs first‐generation antipsychotics | RR 1 [0.42, 2.35] | 16 studies · 640 participants | Very low Downgraded: risk of bias, inconsistency |
Adverse effects: number of participants with at least one adverse effect (short term) Haloperidol vs first‐generation antipsychotics | RR 1.06 [0.94, 1.2] | 10 studies · 693 participants | Low Downgraded: risk of bias, inconsistency |
Adverse effects: extrapyramidal side effects: number of participants with at least one extrapyramidal side effect (short term) Haloperidol vs first‐generation antipsychotics | RR 1.12 [0.95, 1.31] | 17 studies · 998 participants | Very low Downgraded: risk of bias, inconsistency |
Haloperidol versus first‐generation antipsychotics for schizophrenia (medium term)
Population: people with schizophrenia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinically important response to treatment (medium term) Haloperidol vs first‐generation antipsychotics | RR 0.51 [0.37, 0.69] | 1 study · 80 participants | Low Downgraded: risk of bias |
Leaving the study early due to any reason as a measure of overall acceptability (medium term) Haloperidol vs first‐generation antipsychotics | RR 1.02 [0.75, 1.38] | 2 studies · 137 participants | Very low Downgraded: risk of bias |
Leaving the study early due to adverse events as a measure of overall tolerability (medium term) Haloperidol vs first‐generation antipsychotics | no estimate extracted | 1 study · 80 participants | Low Downgraded: risk of bias |
Adverse effects: number of participants with at least one adverse effect (medium term) Haloperidol vs first‐generation antipsychotics | RR 1.07 [0.58, 1.97] | 2 studies · 137 participants | Very low Downgraded: risk of bias |
Adverse effects: extrapyramidal side effects: number of participants with at least one extrapyramidal side effect (medium term) Haloperidol vs first‐generation antipsychotics | RR 1.04 [0.62, 1.75] | 1 study · 80 participants | Very low Downgraded: risk of bias |